Table 2.
Univariate analysis of median overall survival and hazard ratios for risk of mortality according to clinical parameters
| Clinical pathological parameters |
Overall survival |
Risk of mortality |
||
| Month (95%CI) | P value | HR (95%CI) | P value | |
| Performance status | 0.012 | |||
| 0-1 | 14.4 (10.8-17.0) | 1.00 (referent) | ||
| 2 | 7.6 (2.5-13.7) | 3.26 (0.96-16.46) | 0.041 | |
| Histological grade | 0.062 | |||
| Differentiated | 15.5 (8.2-22.5) | 1.00 (referent) | ||
| Undifferentiated | 10.9 (4.5-17.3) | 4.95 (0.92-18.6) | 0.122 | |
| Tumor-node-metastasis stage | 0.001 | |||
| IIIA | 19.3 (16.9-21.7) | 0.87 (0.51-9.76) | < 0.001 | |
| IIIB | 13.0 (7.8-18.2) | 0.92 (0.81-2.15) | 0.102 | |
| IV | 7.2 (4.4-10.0) | 1.00 (referent) | ||
| Chemotherapeutic regimen | 0.536 | |||
| Cisplatin + fluoropyrimidine | 10.7 (5.1-16.3) | 1.00 (referent) | ||
| Cisplatin + docetaxel | 13.2 (7.0-19.4) | 0.84 (0.76-1.79) | 0.073 | |
| Cisplatin + paclitaxel | 12.6 (6.4-18.9) | 0.91 (0.85-2.41) | 0.145 | |
| Cisplatin + capecitabine | 11.3 (5.6-18.0) | 0.98 (0.90-3.26) | 0.210 | |
| Cisplatin + S-1 | 12.0 (6.1-17.9) | 0.95 (0.89-2.84) | 0.179 | |
| ABCG2 mRNA expression times | 0.031 | |||
| ≤ 0.71 | 14.2 (9.7-18.6) | 0.71 (0.43-0.96) | < 0.001 | |
| 0.71-1.8 | 11.4 (6.3-16.5) | 0.94 (0.76-1.52) | 0.083 | |
| ≥ 1.8 | 9.0 (6.4-11.6) | 1.00 (referent) | ||